MapLight Therapeutics, Inc. (MPLT) has received a new Buy rating, initiated by Jefferies analyst, Andrew Tsai.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andrew Tsai has given his Buy rating due to a combination of factors that highlight MapLight Therapeutics, Inc.’s promising pipeline and potential market impact. The company is advancing its novel M1/M4 muscarinic agonist, ML-007C-MA, which is expected to produce significant Phase II data for schizophrenia by the second half of 2026. This development could potentially double the stock’s value and enhance the perceived worth of its Alzheimer’s psychosis program.
Additionally, MapLight’s ML-004, targeting autism spectrum disorder, represents another substantial market opportunity. The company’s strategic positioning in the central nervous system and neuropsychiatric treatment landscape, along with its potential to attract major pharmaceutical interest, supports a positive risk-reward scenario. The anticipated strong intellectual property protection and competitive advantages in efficacy and safety further bolster the Buy recommendation.
Tsai covers the Healthcare sector, focusing on stocks such as Xenon, Biogen, and Alto Neuroscience, Inc.. According to TipRanks, Tsai has an average return of 14.2% and a 55.78% success rate on recommended stocks.
In another report released today, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $34.00 price target.